A B S T R A C T Transfer factor (TF) derived from donors with strong delayed hypersensitivity to coccidioidin (CDN) was administered to four patients with active disseminated or progressive pulmonary coccidioidomycosis. The clinical and immunologic response to TF was studied.
Before the administration of TF, all four patients had defective thymus-derived lymphocyte (T-cell) function. In no case were lymphocytes in culture stimulated to incorporate [3H]thymidine when exposed to CDN. Cases 1 and 2 had no skin test response to CDN or other antigen, nor was antigen-induced migration inhibition factor (MIF) release detected. Cases 3 and 4 had skin reactivity to CDN as well as MIF release. Lymphocyte reactivity to phytohemagglutinin (PHA), as measured by the incorporation of ['H]thymidine, was low or absent in all.
After the administration of TF, patients with negative skin tests became reactive to CDN, MIF release was present in all but case 1, and lymphocyte stimulation was present in response to CDN in all.
Lymphocyte reactivity to PHA was also increased after the administration of TF in all cases. All responses to single doses of TF were transient, lasting no more than 10 days. Subsequent doses were less effective at restoring lymphocyte stimulation once it had waned. Multiple doses of TF administered at frequent intervals appear to be the most effective way to maintain lymphocyte reactivity.
Clinical response to the administration of TF correlated closely with specific transfer as measured by response to CDN in skin test, lymphocyte stimulation, and MIF release. After TF administration, all patients mounted a more effective host response against the 
INTRODUCTION
The variability of clinical response to infection with Coccidioides iminitis has been recognized for many years. Using the development of cutaneous delayed hypersensitivity (CDH) ' to intradermal coccidioidin (CDN), it has been established that 90% of residents in highly endemic areas become infected by C. immitis. Yet, clinical disease is uncommon (1) . In the great majority of instances, the inhaled fungus is contained in the lungs by granuloma formation. Yet, in some, progressive pulmonary disease occurs, and in a small number, the infection disseminates from the lungs to other organs.
Expanding knowledge of the role of cell-mediated immunity (CMI) in conditioning the response to other infections led us to question its potential contribution to the clinical variability of patients infected with C. iutinitis. This question was stimulated by the observation that 50% of patients with disseminated disease failed to develop CDH to intradermal CDN (2) . More recently, we have shown that patients with a poor biologic response to C. immnitis infection have abnormal thymus-derived lymphocyte (T-cell) function in response to both mitogen and specific antigen (3) These data have suggested that enhancement of CMI in such patients might have therapeutic potential. The most promising current avenue for achieving such enhancement is the administration of transfer factor (TF).
TF is a dialyzable extract of immune leukocytes which is capable of transferring cellular immunity from an individual with CDH to CDN to a nonreactive recipient (4) . Therapeutic use of TF began in 1969 in a patient with the Wiskott-Aldrich syndrome ( 5).
Subsequently, it has been used to treat a variety of other illnesses associated with defective cellular immunity (6) . AMore recently TF has been administered to patients with intracellular infections such as mucocutaneous candidiasis (7) (8) (9) , leprosy (10), and coccidioidomycosis (11, 12 Preparation of TF. Donors of TF met the following criteria: (a) They had CDH to intradermal CDN (1: 100) in 48 h of over 20 mm of induration; (b) ['H]thymidine incorporation after lymphocyte culture in the presence of CDN was at least four time greater than control cultures on the 6th day; (c) MIF was released when lymphocytes were cultured in the presence of CDN; (d) Australia antigen was not detected in peripheral blood. Lymphocytes were harvested by leukophoresis of 2 U of whole blood or by leukophoresis on the Aminco cell separator (American Instrument Co., Inc., Silver Springs, Md.). TF was prepared by our modification (5) of the method of Lawrence (4) . The cells were suspended in saline, frozen, thawed, and refrozen until all cells were ruptured, then treated with DNAase and magnesium sulfate. This preparation was placed in a dialysis sac and dialyzed against distilled water. The dialysate was lyophilized and reconstituted in 2 ml normal saline. Each dose was prepared from a single donor and is defined as the amount of TF obtained from 5 X 10'
lymphocytes. The preparations were tested for pyrogenicity and were passed through a 0.22-Am Millipore filter (Millipore Corp., Bedford, Mass.) before use. Ability to cause transfer in normal, nonsensitive individuals was also assayed by skin test, MIF release, and lymphocyte stimulation in response to CDN. TF was given subcutaneously, and in addition, TF was given subcutaneously twice in an attempt to achieve local transfer.
CHARACTERIZATION OF STUDY PATIENTS Clinical status. Case 1 was a 50-yr-old Mexican
American male who was admitted to University Hospital with a 4-mo history of fatigue and weight loss. 2 mo previously, he had developed a nonproductive cough, afternoon fever, and night sweats. 4 wk later, he noted anorexia, weakness, and weight loss. 1 wk before admission, he observed a generalized rash which subsequently evolved into raised lesions on his face and trunk. The fever became persistent and the patient deteriorated (Table II) .
Immunologic responsc to TF. Case 1 was given 1 U of TF subcutaneously on three occasions (Fig. 1) .
The 1st U of TF was divided. 10% was given subcutaneously on the upper arm in preparation for later skin testing. The remainder, as well as the two subsequent doses, was given subcutaneously in the thighs.
Intradermal CDN 1: 10 was applied at two sites 24 h after TF administration. The skin test applied at the site of previous subcutaneous TF administration developed erythema and soft cutaneous edema which measured 20 mm. The skin test applied on normal, unprepared skin produced no reaction. 5 days after the 1st U of TF, [3H]thymidine incorporation after stimulation with CDN was significantly increased. Response to PHA unfortunately was not measured in this first post-TF sample; response to SK-SD was measured and was increased 7.5-fold over control. MIF production was not detected. 14 By the 10th day after TF, the response had returned to base-line levels. The 2nd U of TF, as in Case 2, was followed by a significant thymidine incorporation in control cultures collected 10 days after the administration of TF. The 3rd U also was followed by an with TF had begun. The cause of death was not apparent. Postmortem examination could not be obtained. Case 2 did not receive concomitant amphotericin therapy. The patient improved gradually over several weeks after receiving TF. His sputum production decreased and cultures were negative for C. immitis. His exercise tolerance, weight, and sense of well-being all increased. During the period from the 7th to the 10th mo when TF was withheld, the patient deteriorated dramatically. Sputum production increased, severe hemoptysis occurred, and an area of infiltration observed previously on chest X-ray became a large cavity. Sputum culture was positive for C. immitis and Escherichia coli. TF therapy was reinstituted and sputum culture promptly became negative. Slow clinical improvement followed with increased exercise tolerance and weight gain. CF with CDN was positive to a titer of 1:256. Serial studies revealed no change in titer over the period of 13 mo.
Case 3 had a broncho-mediastinal-retroperitonealcutaneous fistula which drained necrotic material. Bacteriologic study of that material demonstrated C. immitis. The basic therapy that had been administered for 13 mo before study entry, as well as during the study period, consisted of instillation of 50 mg amphotericin into the fistulous tract three times each week. Concurrent with the first three doses of TF, drainage from the fistulas decreased in amount and stopped on the right side. Culture of the wound failed to recover fungi. A sinogram showed no fistula on the right, and on the left the fistula no longer traversed the diaphragm. When TF was not administered through the 9th mo of followup, drainage increased from both fistulas and a sinogram demonstrated re-establishment of both fistulous tracts and their communication with the posterior mediastinal areas and the airway. Renewed TF therapy, given at frequent intervals, resulted in reclosure of the fistula on the right and decreased drainage on the left. (Fig. 6) .
Case 4 had been receiving amphotericin 15 mg/day intravenously at the onset of the study. This was continued for the entire study period. The patient was extremely ill when she received her first dose of TF. Subsequent doses were given regularly until she had received six doses. Over the 2 mo period of TF administration, the patient experienced continuous improvement. She quickly became afebrile; her drainage diminished, then stopped; the fistulous tract healed over; and she regained neurologic function to the point that she was able to walk with ease. During the next 2 mo, she continued to improve with increase of weight, and resumed near normal activity. Radiologically, her pulmonary infiltrates have nearly resolved, a nodule has formed in the lingula and bone lesions appear to be healing (Fig. 7) .
DISCUSSION
The treatment of coccidioidomycosis presents a difficult set of problems. Amphotericin is the only currently available standard agent with activity against C. immitis. Systemic administration of amphotericin is often associated with significant toxic effects; i.e., chills, fever, nausea, shock-like picture, potassium loss, renal failure, and anemia (15) . In addition, the drug is only fungistatic and requires host defense mechanisms to rid the body of infection. Mortality rates in disseminated coccidioidomycosis, particularly acute dissemination, remain high (16) . These patients frequently lack skin reactivity to CDN despite a vigorous antibody response as detected by CF (16) .
In a previous report (3), we demonstrated that patients with a poor biologic response to infection with C. immitis show a defect in skin test reactivity to CDN. They also show defects in cellular immunity in vitro as manifested by failure to undergo lymphocyte stimulation and MIIF release in response to CDN. An abnormal kinetic response in lymphocyte stimulation to CDN and PHA has also been demonstrated.
TF is capable of transferring skin test reactivity from a skin test positive donor to a skin test negative normal recipient (17) . Not only skin reactivity but also in vitro parameters of cellular immunity are transferred (18) . TF is exceedingly potent, the amount contained in 0.1 ml of packed leukocytes being sufficient to transfer systemic reactivity to a normal individual (19) . These observations led to attempts to use TF therapeutically to reconstitute patients with diminished cellular immunity (6) (7) (8) (9) (10) (11) (12) . In these conditions TF has been clearly shown to cause conversion of skin tests and in vitro tests of cellular immunity. However, clinical response is more difficult to assess.
The administration of TF to patients with coccidioidomycosis offers a unique opportunity to study several interrelated questions. What is the nature of the defect in CMI in patients wvitlh coccidioidomvcosis ? Can it be corrected by TF? What effect does TF have on the course of clinical disease? Is that effect related to specific immunologic action of TF? In this study we chose not to discontinue the administration of amphotericin in those patients who were receiving it (cases 1, 2, and 4) since the disease was considered life-threatening and the efficacy of TF is unproven. The prognosis in case 1 was bleak. Fatality in patients with acute coccidioidal fungemia has been reported to be 100% (16) . Cases 2 and 4 had had a long period of observation on standard therapy which served as an internal control. Case 3 was treated with TF alone. All patients in this study showed a defect in cellular immunity to CDN in at least one of the three tests used (skin reactivity, lymphocyte stimulation, or MIF release). Clinical response to infection was inadequate in all patients. As indicated above case 1 had a bleak prognosis. Cases 2, 3. and 4 had not been able to clear the infection even after 2-18 yr of conventional therapy. With the exception of the MIF release, which remained negative in case 1, all three tests of the cellular immune response became positive, at least temporarily, in all the patients after the administration of TF from donors sensitive to CDN. The most striking effect of the administration of TF was on the transfer of specific response to CDN in lvml- phocyte stimulation. No patient had lymphocyte stimulation by CDN before TF; all became positive after TF. We did not determine the specificity of transfer by the administration of TF derived from the donors without sensitivity to CDN.
The transient nature of the transferred immunity in the patients presented is in contrast with the reported results in normal where evidence in skin and in vitro for transferred sensitivity persists for months to years (19) . In our patients, the conversion of skin test reactivity was transient. Increased lymphocyte stimulation to CDN, which appeared within 24 h of administration of one dose of TF, was lost usually within 10 days. Subsequent A major concern before the initiation of TF therapy was whether the sudden re-establishment of specific cellular immunity in patients with widespread infection might result in an overwhelming adverse reaction. In the studies by Bullock in patients with leprosy, major systemic adverse effects of TF were not observed (10) . Case 1 was of particular concern since he had coccidioidal fungemia and miliary disease to the extent that pulmonary gas exchange was greatly impaired. With the administration of TF his gas exchange did not deteriorate. His 
